Randomized Controlled Multi-center Short Course Treatment for Rifampicin Resistant Tuberculosis

Inclusion Criteria: * signed informed consent and accepted follow-up; * the age is between 18 and 65 years old, both male and female, including inpatients and outpatients; * no use of anti tuberculosis drugs, or use of anti tuberculosis drugs less than 1 month; * the results of molecular biology test confirmed rifampicin resistance or MDR-TB patients; * chest CT examination confirmed pulmonary tuberculosis, pulmonary lesions, or cavity; * premenopausal women had negative pregnancy urine test and agreed to use high-efficiency contraceptive measures during the study period. Exclusion Criteria: * drug sensitivity test or molecular drug sensitivity results show that the drug resistance (except isoniazid) or any component of the drug has a history of allergy, or is taking any drug that is contraindicated to the drug in the short-term treatment program; * severe renal insufficiency (creatinine clearance rate (CrCl) less than 30 ml / min). * liver function impairment (ALT and / or AST level 3 times higher than the upper limit of laboratory reference value, if it is temporary increase, it can be included after treatment recovery); * those who are unable to participate in or comply with the treatment and follow-up; * Q-T interval \> 450 millisecond; * have a history of cardiovascular diseases or are suffering from such diseases as heart failure, hypertension (poor blood pressure control), arrhythmia or post myocardial infarction state; * pregnant or lactating women; * those who are unable to take oral drugs; * those who are currently participating in other clinical trials; * patients with HIV positive or active viral hepatitis.